東華大學圖書館 |

Development and Validation of Technology for Fluorescence Detection and Enumeration of Extremely Rare Circulating Cells in vivo.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Development and Validation of Technology for Fluorescence Detection and Enumeration of Extremely Rare Circulating Cells in vivo./
作者:	Tan, Xuefei.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	160 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
Contained By:	Dissertations Abstracts International81-04B.
標題:	Electrical engineering. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22621688
ISBN:	9781687967107

Development and Validation of Technology for Fluorescence Detection and Enumeration of Extremely Rare Circulating Cells in vivo.
Tan, Xuefei.

Development and Validation of Technology for Fluorescence Detection and Enumeration of Extremely Rare Circulating Cells in vivo. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 160 p.

Source: Dissertations Abstracts International, Volume: 81-04, Section: B.

Thesis (Ph.D.)--Northeastern University, 2019.

This item is not available from ProQuest Dissertations & Theses.

Circulating tumor cells (CTCs) and CTC clusters are of great interest in studying cancer metastasis, but methods for their enumeration remain far from optimal. Current methods for enumeration of CTCs in blood rely on drawing, storing, and enriching blood samples, but these technologies may yield significant cell count errors and artifacts, and break up clusters into single cells. A promising set of technologies termed "in vivo flow cytometry" (IVFC) avoid the drawbacks of drawing blood samples, and allow continuous measurement of circulating cell populations over time rather than at discrete time points. However, microscopy-IVFC is poorly suited for detecting rare CTCs in cancer metastasis, where biologically significant numbers may be fewer than 100 cells per mL of peripheral blood. In this dissertation, we developed and performed first in vivo demonstration of a new technique called "Diffuse in vivo Flow Cytometry" (DiFC). This technology is based on a special optical fiber probe design that allows fluorescence detection of labeled circulating cells flowing in large superficial blood vessels without drawing blood samples. We first validated and characterized the fiber probe design, and showed that it significantly simplified the operation and improved signal-to-noise characteristics versus our previous work. We then developed a dual-channel DiFC design and new signal processing algorithm to analyze DiFC data. The dual-channel DiFC design allows counting of individual cells moving in arterial or venous directions, which avoids multiple counting of cells and excludes false alarms due to motion artifacts or electronic noise. We also demonstrated that DiFC allows sampling of the entire peripheral blood volume of a mouse in minutes while maintaining a false alarm rate below one per hour.To explore potential applications of DiFC, we performed a detailed characterization of DiFC capabilities. Tissue-mimicking flow phantom experiments showed that DiFC has over 95% accuracy of counting cells in the range of 0.1 to 100 detections per minute, at depths up to 2 mm in bulk scattering media, while accurately identifying the direction and speed of cells in 1-500 mm per second range. DiFC also allows detection of cells labeled with at least 105 fluorophores per cell. We then applied DiFC to non-invasively monitor CTC burden over time in a multiple myeloma disseminated xenograft model in mice. We demonstrated that the unprecedented in vivo sensitivity of DiFC allows early detection of CTC dissemination at burdens of 1 cell per mL of peripheral blood. DiFC also, for the first time in literature, detected dissemination of CTC clusters (CTCCs) in the early development of MM in vivo. We also applied DiFC for long term and non-invasive monitoring of erythrocyte camouflaged fluorescence microsensors in circulation and discussed the potential application in personalized medicine. In combination, these capabilities indicate that DiFC can be applied in a broad range application in biomedical research. We discuss future applications of DiFC and ongoing areas of technical development for DiFC.

ISBN: 9781687967107Subjects--Topical Terms:

649834
Electrical engineering.
Subjects--Index Terms:

Biomedical Instrument

Development and Validation of Technology for Fluorescence Detection and Enumeration of Extremely Rare Circulating Cells in vivo.
LDR:04475nmm a2200397 4500 001 2348030
005 20220906075147.5
008 241004s2019 ||||||||||||||||| ||eng d
020 $a 9781687967107
035 $a (MiAaPQ)AAI22621688
035 $a AAI22621688
040 $a MiAaPQ $c MiAaPQ
100 1 $a Tan, Xuefei. $3 3687350
245 1 0 $a Development and Validation of Technology for Fluorescence Detection and Enumeration of Extremely Rare Circulating Cells in vivo.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 160 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
500 $a Advisor: Niedre, Mark.
502 $a Thesis (Ph.D.)--Northeastern University, 2019.
506 $a This item is not available from ProQuest Dissertations & Theses.
506 $a This item must not be sold to any third party vendors.
520 $a Circulating tumor cells (CTCs) and CTC clusters are of great interest in studying cancer metastasis, but methods for their enumeration remain far from optimal. Current methods for enumeration of CTCs in blood rely on drawing, storing, and enriching blood samples, but these technologies may yield significant cell count errors and artifacts, and break up clusters into single cells. A promising set of technologies termed "in vivo flow cytometry" (IVFC) avoid the drawbacks of drawing blood samples, and allow continuous measurement of circulating cell populations over time rather than at discrete time points. However, microscopy-IVFC is poorly suited for detecting rare CTCs in cancer metastasis, where biologically significant numbers may be fewer than 100 cells per mL of peripheral blood. In this dissertation, we developed and performed first in vivo demonstration of a new technique called "Diffuse in vivo Flow Cytometry" (DiFC). This technology is based on a special optical fiber probe design that allows fluorescence detection of labeled circulating cells flowing in large superficial blood vessels without drawing blood samples. We first validated and characterized the fiber probe design, and showed that it significantly simplified the operation and improved signal-to-noise characteristics versus our previous work. We then developed a dual-channel DiFC design and new signal processing algorithm to analyze DiFC data. The dual-channel DiFC design allows counting of individual cells moving in arterial or venous directions, which avoids multiple counting of cells and excludes false alarms due to motion artifacts or electronic noise. We also demonstrated that DiFC allows sampling of the entire peripheral blood volume of a mouse in minutes while maintaining a false alarm rate below one per hour.To explore potential applications of DiFC, we performed a detailed characterization of DiFC capabilities. Tissue-mimicking flow phantom experiments showed that DiFC has over 95% accuracy of counting cells in the range of 0.1 to 100 detections per minute, at depths up to 2 mm in bulk scattering media, while accurately identifying the direction and speed of cells in 1-500 mm per second range. DiFC also allows detection of cells labeled with at least 105 fluorophores per cell. We then applied DiFC to non-invasively monitor CTC burden over time in a multiple myeloma disseminated xenograft model in mice. We demonstrated that the unprecedented in vivo sensitivity of DiFC allows early detection of CTC dissemination at burdens of 1 cell per mL of peripheral blood. DiFC also, for the first time in literature, detected dissemination of CTC clusters (CTCCs) in the early development of MM in vivo. We also applied DiFC for long term and non-invasive monitoring of erythrocyte camouflaged fluorescence microsensors in circulation and discussed the potential application in personalized medicine. In combination, these capabilities indicate that DiFC can be applied in a broad range application in biomedical research. We discuss future applications of DiFC and ongoing areas of technical development for DiFC.
590 $a School code: 0160.
650 4 $a Electrical engineering. $3 649834
650 4 $a Bioengineering. $3 657580
650 4 $a Optics. $3 517925
653 $a Biomedical Instrument
653 $a Cancer Detection
653 $a Cells Enumeration
653 $a Fluorescence Detection
653 $a in vivo Flow Cytometry
653 $a Rare Circulating Cells
690 $a 0544
690 $a 0202
690 $a 0752
710 2 $a Northeastern University. $b Electrical and Computer Engineering. $3 1018491
773 0 $t Dissertations Abstracts International $g 81-04B.
790 $a 0160
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22621688